Literature DB >> 19540225

Effect of postnatal methamphetamine trauma and adolescent methylphenidate treatment on adult hippocampal neurogenesis in gerbils.

Andrea T Schaefers1, Gertraud Teuchert-Noodt, Francesco Bagorda, Susanne Brummelte.   

Abstract

Methylphenidate (e.g. Ritalin) is the most common drug used in the treatment of attention-deficit hyperactivity disorder. However, only a few studies have investigated the neuroanatomical long-term effects of this treatment. Prolonged application of methylphenidate during adolescence causes alterations in dopaminergic fiber or receptor densities in adult rodents. This study was conducted to investigate the effects of adolescent methylphenidate treatment on adult hippocampal neurogenesis in male gerbils (Meriones unguiculatus). Animals were first treated with either a single methamphetamine challenge on postnatal day 14 (to cause a disturbance in the dopaminergic system, to mimic the disturbed dopaminergic system seen in ADHD children) or saline and then received a daily oral application of 5 mg/kg methylphenidate or water from postnatal day 30-60 or were left undisturbed. On postnatal 90 gerbils were injected with bromodeoxyuridine (BrdU, a DNA synthesis marker) and sacrificed seven days later. Results reveal that the pretreatment with methamphetamine causes a decrease in the number of BrdU-positive cells in the dentate gyrus. Methylphenidate treatment however did not cause any differences in the number of labelled cells in any group. This implies that, despite methylphenidate's efficiency in inducing changes in the dopaminergic system and associated areas, it might be less effective in altering neurogenesis in the hippocampus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19540225     DOI: 10.1016/j.ejphar.2009.06.006

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Methylphenidate Causes Behavioral Impairments and Neuron and Astrocyte Loss in the Hippocampus of Juvenile Rats.

Authors:  Felipe Schmitz; Paula Pierozan; André F Rodrigues; Helena Biasibetti; Matheus Grunevald; Letícia F Pettenuzzo; Giselli Scaini; Emilio L Streck; Carlos A Netto; Angela T S Wyse
Journal:  Mol Neurobiol       Date:  2016-06-21       Impact factor: 5.590

2.  Chronic administration of amphetamines disturbs development of neural progenitor cells in young adult nonhuman primates.

Authors:  Rahul R Dutta; Michael A Taffe; Chitra D Mandyam
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2018-03-28       Impact factor: 5.067

3.  Chronic D-amphetamine administered from childhood to adulthood dose-dependently increases the survival of new neurons in the hippocampus of male C57BL/6J mice.

Authors:  E C Dabe; P Majdak; T K Bhattacharya; D S Miller; J S Rhodes
Journal:  Neuroscience       Date:  2012-11-20       Impact factor: 3.590

4.  Neurogenesis within the hippocampus after chronic methylphenidate exposure.

Authors:  Hannah V Oakes; Carley E DeVee; Brandon Farmer; Serena A Allen; Alexis N Hall; Tucker Ensley; Kristen Medlock; Angela Hanley; Brooks B Pond
Journal:  J Neural Transm (Vienna)       Date:  2018-10-28       Impact factor: 3.575

Review 5.  Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins.

Authors:  Mario Herrera-Marschitz; Paola Morales; Lisette Leyton; Diego Bustamante; Verena Klawitter; Pablo Espina-Marchant; Camilo Allende; Francisco Lisboa; Gabriel Cunich; Antonella Jara-Cavieres; Tanya Neira; Manuel A Gutierrez-Hernandez; Victor Gonzalez-Lira; Nicola Simola; Andrea Schmitt; Micaela Morelli; R Andrew Tasker; Peter J Gebicke-Haerter
Journal:  Neurotox Res       Date:  2010-07-20       Impact factor: 3.911

6.  Methylphenidate enhances neuronal differentiation and reduces proliferation concomitant to activation of Wnt signal transduction pathways.

Authors:  Edna Grünblatt; Jasmin Bartl; Susanne Walitza
Journal:  Transl Psychiatry       Date:  2018-03-01       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.